Jan 29, 2019 - Allergan Plc (NYSE:AGN) Q4 2018 Earnings Conference Call January 29, 2019 08:30 AM ET Company Participants Manisha Narasimhan - Investor Relations Brenton L. Saunders - Chairman, President & CEO W
Jan 29, 2019 - Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.
Jan 28, 2019 - Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Jan 24, 2019 - Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.
Jan 20, 2019 - The answer: It's complicated.
Jan 18, 2019 - The increases can mean higher costs for pharmacies and patients on what are generally cheaper generic drugs. Drugmakers say the price increases reflect higher costs they have incurred to help fill supply voids.
Jan 16, 2019 - Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C
Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.